Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents

Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents

Bibliographic Details
Main Authors:	Danielle Hammond, Sanam Loghavi, Sa A. Wang, Marina Y. Konopleva, Tapan M. Kadia, Naval G. Daver, Maro Ohanian, Ghayas C. Issa, Yesid Alvarado, Nicholas J. Short, Koji Sasaki, Naveen Pemmaraju, Guillermo Montalban-Bravo, Curtis A. Lachowiez, Abhishek Maiti, Guillermo Garcia-Manero, Elias J. Jabbour, Gautam Borthakur, Farhad Ravandi, Koichi Takahashi, Sherry R. Pierce, Hagop M. Kantarjian, Courtney D. DiNardo
Format:	Article
Language:	English
Published:	Nature Publishing Group 2023-09-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-023-00915-6

Similar Items

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
by: Musa Yilmaz, et al.
Published: (2022-05-01)

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens
by: Abhishek Maiti, et al.
Published: (2020-06-01)

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
by: Nicholas J. Short, et al.
Published: (2023-07-01)

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
by: Abhishek Maiti, et al.
Published: (2021-02-01)

Acute myeloid leukemia: current progress and future directions
by: Hagop Kantarjian, et al.
Published: (2021-02-01)

P736: ANALYSIS OF RESPONSE RATES AND OUTCOMES IN ERYTHROID-PREDOMINANT MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH VENETOCLAX-BASED REGIMENS
by: Alexandre Bazinet, et al.
Published: (2023-08-01)

P723: CLINICAL AND MOLECULAR ASSOCIATIONS WITH OUTCOMES IN HIGHER RISK MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS PLUS VENETOCLAX
by: Alexandre Bazinet, et al.
Published: (2023-08-01)

P485: AZACITIDINE, VENETOCLAX AND GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA: A SUBGROUP ANALYSIS FROM A PHASE II STUDY
by: Nicholas Short, et al.
Published: (2023-08-01)

AML-348 A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies
by: Lachowiez, C, et al.
Published: (2022)

Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study
by: Patrick K. Reville, et al.
Published: (2021-03-01)

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure
by: Nicholas J. Short, et al.
Published: (2022-01-01)

P763: VENETOCLAX WITH AZACITIDINE IN RELAPSE/REFRACTORY HIGHER RISK MYELODYSPLASTIC SYNDROME: UPDATED PHASE 1 RESULTS
by: S. P. Desikan, et al.
Published: (2022-06-01)

A phase Ib/II study of ivosidenib with venetoclax plus /- azacitidine in IDH1-mutated myeloid malignancies
by: Lachowiez, CA, et al.
Published: (2021)

A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies
by: Lachowiez, CA, et al.
Published: (2022)

S172: PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
by: Alex Bataller, et al.
Published: (2023-08-01)

P748: IPSS-M PERFORMANCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT THE TIME OF HYPOMETHYLATING AGENT FAILURE
by: Samuel Urrutia, et al.
Published: (2023-08-01)

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
by: Musa Yilmaz, et al.
Published: (2020-10-01)

Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
by: Musa Yilmaz, et al.
Published: (2021-02-01)

Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
by: Naval Daver, et al.
Published: (2015-05-01)

A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis
by: Jayastu Senapati, et al.
Published: (2023-06-01)

P500: SUPERIOR OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AMONG PATIENTS ≥ 60 YEARS TREATED WITH CLADRIBINE, LOW DOSE CYTARABINE PLUS VENETOCLAX FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
by: Jayastu Senapati, et al.
Published: (2023-08-01)

A phase Ib/II study of ivosidenib with venetoclax ± azacitidine in IDH1-mutated myeloid malignancies
by: Lachowiez, CA, et al.
Published: (2023)

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
by: Kamal Chamoun, et al.
Published: (2019-01-01)

P377: A PHASE II TRIAL OF MINI-HYPER-CVD WITH VENETOCLAX FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) PHILADELPHIA CHROMOSOME (PH)-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
by: Fadi Haddad, et al.
Published: (2023-08-01)

S127: QUIZARTINIB WITH DECITABINE AND VENETOCLAX (TRIPLET) IS ACTIVE IN PATIENTS WITH FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA - A PHASE I/II STUDY
by: M. Yilmaz, et al.
Published: (2022-06-01)

Outcomes and genetic dynamics of acute myeloid leukemia at first relapse
by: Alex Bataller, et al.
Published: (2024-05-01)

Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series
by: Ahmad S. Alotaibi, et al.
Published: (2020-10-01)

P784: A PHASE I/II STUDY OF VENETOCLAX IN COMBINATION WITH ASTX727 (DECITABINE/CEDAZURIDINE) IN TREATMENT‐NAÏVE HIGH‐RISK MYELODYSPLASTIC SYNDROME (MDS) OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
by: S. Venugopal, et al.
Published: (2022-06-01)

Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies
by: Gautam Borthakur, et al.
Published: (2013-02-01)

P730: EVOLUTION OF IPSS-M RISK CATEGORIES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES FROM DIAGNOSIS TO HYPOMETHYLATING AGENT FAILURE
by: Kelly Chien, et al.
Published: (2023-08-01)

P535: OUTCOMES OF INVESTIGATIONAL AGENTS VS STANDARD THERAPIES IN AML AT SALVAGE 2 AND BEYOND
by: Daniel Nguyen, et al.
Published: (2023-08-01)

Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States
by: Iman Abou Dalle, et al.
Published: (2019-11-01)

Current status and research directions in acute myeloid leukemia
by: Hagop Kantarjian, et al.
Published: (2024-09-01)

P585: IMPACT OF MYELOID MUTATION PROFILE ON PCR RESPONSES AND SURVIVAL IN PATIENTS WITH CORE-BINDING FACTOR AML TREATED WITH FLAG BASED REGIMES
by: Jayastu Senapati, et al.
Published: (2023-08-01)

P760: PATTERNS OF HYPOMETHYLATING AGENT FAILURE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
by: K. Chien, et al.
Published: (2022-06-01)

Relapse and death during first remission in acute myeloid leukemia
by: Masamitsu Yanada, et al.
Published: (2008-04-01)

Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
by: Nicholas J. Short, et al.
Published: (2019-02-01)

P496: PHENOTYPIC SUBTYPES OF LEUKEMIC TRANSFORMATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA
by: Guillermo Montalban-Bravo, et al.
Published: (2023-08-01)

Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia
by: Aziz Nazha, et al.
Published: (2012-08-01)

A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome
by: Mahesh Swaminathan, et al.
Published: (2021-04-01)